Abstracts tagged "Ankylosing spondylitis (AS) and anti-TNF therapy"

Abstract Number: 1528 • 2013 ACR/ARHP Annual Meeting
Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity
Suzanne Arends^1,2, Eveline van der Veer³, Fleur B.S. Kamps⁴, Monique Efde², Martha K. Leijsma⁴, Hendrika Bootsma¹, Elisabeth Brouwer⁵ and Anneke Spoorenberg^2,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁵Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Tumor necrosis factor-alpha (TNF-α) blocking agents are very effective in controlling inflammation and improving clinical assessments in patients with ankylosing spondylitis (AS). In view…
Abstract Number: 1534 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody Injected Subcutaneously Every 4 Weeks, In Chinese Patients With Active Ankylosing Spondylitis: 1-Year Results Of a Phase 3, Randomized, Placebo-Controlled Study
Chunde Bao¹, Feng Huang², Muhammad Asim Khan³, Kaiyin Fei⁴, Zhong Wu⁴, Yanli Zhuang⁴, Timothy A. Gathany⁵, Chenglong Han⁵ and Elizabeth C. Hsia⁴, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Dept of Rheumatology, Chinese PLA General Hospital, Beijing, China, ³Medicine/ Rheumatology, Case Western Reserve University Hospital, Cleveland, OH, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Janssen Global Services, LLC., Malvern, PA
Background/Purpose: A multicenter, randomized, placebo (PBO)-controlled study of golimumab (GLM) was performed in Chinese pts with ankylosing spondylitis (AS). To assess efficacy and safety of…
Abstract Number: 529 • 2013 ACR/ARHP Annual Meeting
Ankylosing Spondylitis and Dysfunctional Dkk
Rajbir Gulati¹, Maripat Corr², Michael H. Weisman³ and David Hallegua⁴, ¹Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, ²Medicine, Univ of California-San Diego, La Jolla, CA, ³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Medicine, Cedars-Sinai/UCLA, Beverly Hills, CA
Background/Purpose: Ankylosing Spondylitis (AS) is characterized by inflammation of the spine and entheses followed by formation of syndesmophytes. Wnt pathway is a regulator of bone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].